Home/Pipeline/AMBAR®

AMBAR®

Alzheimer's Disease

ClinicalActive

Key Facts

Indication

Alzheimer's Disease

Phase

Clinical

Status

Active

Company

Grifols

About Grifols

Grifols is a Spanish multinational pharmaceutical and chemical company that develops plasma-derived medicines and other biopharmaceuticals for patients with chronic and rare diseases. Founded in 1909 in Barcelona, the company has grown into a global leader in plasma collection and fractionation, with operations spanning biopharma, diagnostics, bio supplies, and hospital healthcare solutions. The company is publicly traded and has been recognized by TIME magazine and Forbes as one of the world's best companies and employers for multiple consecutive years.

View full company profile

Therapeutic Areas

Immunology Hepatology Pulmonology Hematology Neurology Infectious Diseases Intensive Care

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
Donanemab	Eli Lilly	Phase 3	Regulatory Review
ALN-APP	Alnylam Pharmaceuticals	Phase 1	Active
Alzheimer's Disease Program	Roche	Various	Active
UCB0022	UCB	Phase 1	Active
Lecanemab (Leqembi)	Eisai	Commercial	Approved
ARO-MAPT	Arrowhead Pharmaceuticals	Pre-clinical	Active
Lu AG08854 (L1CAM mAb)	Lundbeck	Preclinical	Research stage
DNL919	Denali Therapeutics	Phase 1b	Active
BAN2802	BioArctic AB	Preclinical	Back-up candidate
Lecanemab SC	BioArctic AB	Phase 3	Active (Study 302)
Undisclosed Program	uniQure	Preclinical	Research
NVG-291	NervGen Pharma	Phase 1b/2a	Active, not yet recruiting